Eli Lilly just took 2 major steps forward in the billion-dollar obesity drug market. Here's what you need to know.

Eli Lilly has seen revenue and earnings soar in recent years.

Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious ...

Trade Tracker: Rich Saperstein buys more Pfizer and Bristol Myers

Richard Saperstein, Chief Investment Officer at Treasury Partner, joins CNBC's Halftime Report to detail his latest portfolio ...

Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment

Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a ...

These 4 charts show the scale of Novo Nordisk's woes

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.
Opinion

15 states sue Trump administration over changes to U.S. vaccine schedule

Democrats sue the Trump administration over the CDC's recent changes to the U.S. childhood vaccine schedule. Read more here.

Pfizer's Strategic Push into China's Weight-Loss Drug Arena

Pfizer's obesity-related pipeline is gaining substantial momentum. On February 3, 2026, the company announced positive Phase 2b results from its VESPER-3 study for PF-08653944, a long-acting ...

Madrigal: The Easiest Money May Have Been Made

Madrigal has made three in-licensing deals since July 2025, picking up multiple potential MASH therapeutics. Read why MDGL ...

Is Pfizer (PFE) Offering Value After Mixed Multi Year Share Price Performance

If you are wondering whether Pfizer's current share price offers value or just noise, this article walks through what the numbers actually say about the stock. Pfizer's recent share price reflects ...